Menlo Therapeutics (NASDAQ:MNLO) issued its quarterly earnings data on Wednesday. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.33, Fidelity Earnings reports.
NASDAQ MNLO traded down $0.22 on Thursday, reaching $6.89. 5,336 shares of the stock were exchanged, compared to its average volume of 123,605. Menlo Therapeutics has a one year low of $5.40 and a one year high of $39.86. The stock has a market cap of $158.55 million and a price-to-earnings ratio of -1.20.
Several equities analysts have recently weighed in on MNLO shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $25.00 price objective on shares of Menlo Therapeutics in a research note on Monday, October 8th. Roth Capital started coverage on shares of Menlo Therapeutics in a research note on Tuesday, July 24th. They issued a “buy” rating and a $29.00 price objective on the stock. KeyCorp started coverage on shares of Menlo Therapeutics in a research note on Tuesday, July 24th. They issued a “buy” rating on the stock. ValuEngine upgraded shares of Menlo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Zacks Investment Research upgraded shares of Menlo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Friday, October 12th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $24.43.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/11/08/menlo-therapeutics-mnlo-posts-quarterly-earnings-results-beats-estimates-by-0-33-eps.html.
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.
See Also: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.